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Abstract: Objectives: To determine preference, satisfaction, usability and local tolerability by patients, physicians and 
study nurses of two subcutaneously administered methotrexate (MTX) formulations of different concentrations. 
Methods: This was an open-label, comparative, within-patient controlled, multicentre study of 132 patients with 
rheumatoid arthritis (RA). MTX treatment consisted of 20 mg/week administered as a medium-concentration formulation 
(MC) (2.0 ml of 10  mg/ml solution in prefilled syringe; separate needle) compared to a novel high-concentration 
formulation (HC) (0.4 ml of 50 mg/ml in prefilled syringe; pre-attached needle). Each treatment was given for three 
weeks. Questionnaires and visual analogue scales were used to measure outcomes. 
Results: At the end of the study, 93% of the patients preferred HC over MC as further treatment. Overall assessment of 
HC was “good” or “very good” in 90.6% vs 34.4% in MC-treated patients. Physician’s and patients global assessment of 
syringe usability showed highly statistically significant differences (P < 0.0001) in favour of HC. Overall assessment by 
study nurses’ and investigators’ was “good” (18.8%) or “very good” (81.2%) for HC and “good” in 31.3% or “very good” 
in 12.5% for MC, and no preference in 50%. Local tolerability improved slightly also with HC. 
Conclusions:  The total smaller volume of administered drug and the improved usability of a pre-attached needle in 
combination with a smaller prefilled syringe resulted in preference of the patients of HC over MC. The slightly improved 
local tolerability may also have added to this preference. This assessment was confirmed by similar assessments made by 
healthcare professionals. 
Eudra-CT number: 2007-003591-19. 
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INTRODUCTION 
  In the past decade, low-dose methotrexate (MTX) has 
become the disease-modifying antirheumatic drug of choice 
in the treatment of rheumatoid arthritis (RA). 
Subcutaneously (SC) administered MTX is well absorbed, 
appears to overcome the problems associated with oral 
administration, including variable absorption and saturation 
of the absorption mechanism with increasing doses, and is  
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well tolerated [1]. Recent studies have also confirmed the 
improved usability and tolerability of subcutaneous 
application [2-4], in particular in comparison to 
intramuscular injection [2]. However, several patients still 
experience problems to apply several millilitres of liquid 
MTX every week and report also local side effects associated 
with the injected volume. 
  A 6-month, prospective, randomized, double-dummy 
trial compared the efficacy and safety of SC versus oral 
administration of MTX in 384 patients with RA [5]. Patients 
were randomly assigned to receive 15 mg/week of MTX 
either orally (two 7.5 mg tablets) or SC (prefilled syringe 
containing 10 mg/ml). After 6 months, significantly more 16   The Open Rheumatology Journal, 2010, Volume 4  Müller-Ladner et al. 
patients treated with SC MTX than with oral MTX showed 
ACR20 (78% vs 70%) and ACR70 (41% vs 33%) responses. 
Patients with disease duration  12 months had even higher 
ACR20 response rates (89% for SC administration and 63% 
for oral). Tolerability did not differ between the two groups. 
  In a phase I study, 12 healthy male subjects received 
15  mg MTX SC either as 50  mg/ml solution or as a 
10 mg/ml concentration. Both concentrations were shown to 
be bioequivalent with regard to AUC (medac, data on file). 
However, the rate of absorption expressed by Cmax was 
different with higher Cmax concentrations achieved after 
administration of the higher concentrated solution. For the 
metabolite 7-hydroxy-MTX, similarity in rate and extent of 
absorption for SC administration was confirmed. Because of 
the bioequivalence of AUC of both concentrations, no 
difference in the efficacy and the safety of the two 
formulations was expected. Local tolerability was similar in 
both groups. Only three cases of mild erythema were 
observed (one with the concentration of 50 mg/ml and two 
with the concentration of 10  mg/ml). All events occurred 
immediately after injection and resolved within 2 hours after 
injection. 
  The objectives of the subsequent study were the direct 
comparisons of local tolerability, usability, satisfaction and 
preference of two MTX solutions with different 
concentrations after SC administration in a larger number of 
patients with RA. 
STUDY PARTICIPANTS AND METHODS 
Objectives 
  The primary study objective was to assess the overall 
preference of RA patients for continuous MTX treatment 
with either the medium-concentration formulation (MC) (2.0 
ml of 10 mg/ml solution; need to apply needle) or the high-
concentration formulation (HC) (0.4  ml of 50  mg/ml pre-
filled syringe; pre-attached needle) by repeated SC inject-
ions. 
  Secondary objectives included satisfaction, usability and 
local tolerability assessed by patients, physicians and study 
nurses. 
Study Design 
  This open, comparative, within-patient controlled, 
multicentre study enrolled 132 patients at 16 centres in 
Germany between November 2007 and November 2008. 
Patient enrolment by centre ranged between 1 and 24 
patients. Patients received 20 mg MTX administered SC via 
MC (2 ml of the 10 mg/ml solution) once weekly for 3 
weeks followed by HC (0.4 ml of the 50 mg/ml solution) for 
another three weeks. The physicians or the study nurses 
performed the first injection of every type of syringe (1
st and 
4
th injection within the study), the following two injections 
of every type of syringe were performed by the patients 
themselves (2
nd, 3
rd, 5
th and 6
th injection within the study). 
Questionnaires and visual analogue scales were used to 
document satisfaction, usability and local tolerability. Safety 
laboratory testing (haematology and biochemistry) were 
performed at baseline, after 3 weeks and at the end of the 
study. 
Patients 
  The study included patients with a diagnosis of RA 
according to the ACR criteria [6]. Patients were 18 to 75 
years old and had received oral MTX- which is among 
parenteral application also in accordance with national 
recommendations for treatment of RA [7] - for at least 6 
weeks prior to study start and required an intensified therapy 
due to remaining RA activity (DAS28 > 2.6). After study 
termination every patient received appropriate RA treatment 
at the discretion of the investigator. 
  The main exclusion criteria were: prior treatment with 
parenteral MTX or biologicals; concomitant treatment with 
another DMARD or a biological; renal insufficiency (serum 
creatinine  > 1.5 x ULN); liver function test abnormalities 
(AST or ALT > 2 x ULN, bilirubin > 5 mg/dl); impaired 
haematopoiesis (platelets < 100 x 10
9/l, leukocytes < 3.5 x 
10
9/l), anaemia (haemoglobin < 10 g/dl); severe acute or 
chronic infections; malignant disease; alcohol or drug 
addiction; history of generalised allergic reactions or serious 
adverse reactions to the study medication or other 
components of the injection solution; women with child-
bearing potential without reliable contraception; men who 
had a partner with child-bearing potential and did not use a 
condom or a cervical cap/diaphragm with spermicide during 
the study and for at least 6 months thereafter; pregnant or 
breast-feeding women; any other subcutaneously adminis-
tered drugs (e.g. insulin, heparin); concurrent vaccination 
with live vaccines. 
  Previous therapy with other DMARDs and concomitant 
therapy with nonsteroidal antirheumatic drugs or corticoste-
roids were permitted during the study: combination therapy 
with one or more DMARDs or a biological immuno-
modulator (e.g. TNF- blockers); drugs causing folate defic-
iency (e.g. sulfonamides, trimethoprim-sulfamethoxazole); 
live-virus vaccinations. Patients were allowed to receive oral 
folic acid once a week, 24 hours after the MTX dose, with 
the dose to remain constant throughout the study. 
Assessment of Patient-Reported, Physician-Reported and 
Study Nurse/Physician-Reported Outcomes 
 Table  1 summarises questions and answers concerning 
patient-reported, physician-reported and study nurse/physi-
cian-reported outcomes. 
Assessment of Safety 
  All patients who received at least one dose of study 
medication were evaluated for the occurrence of adverse 
events, serious adverse events and clinical laboratory 
abnormalities. Severity of adverse events was assessed by 
the investigator as mild, moderate, severe and life-
threatening whereas clinical laboratory values were judged 
with respect to clinical significance. 
Study Medication 
  Study drug consisted of the commercially available MTX 
medium-concentration formulation (10 mg/ml solution; need 
to apply a needle; metex
  in Germany, metoject
 in other 
countries, manufacturer: medac Gesellschaft für klinische 
Spezialpräparate mbH, Hamburg, Germany) and a prefilled Comparison of Two MTX Prefilled Syringes for S.C. Injection in RA  The Open Rheumatology Journal, 2010, Volume 4   17 
syringe MTX high-concentration formulation (50  mg/ml 
solution; pre-attached needle) (Fig. 1); both formulations 
were provided by medac GmbH, Germany. 
Statistical Analysis 
  The primary objective, i.e. the proportion of patients 
deciding in favour of the HC syringe, was subjected to 
statistical testing by applying a two-sided one-group chi-
square test on a significance level of 5%. For sample size 
estimation, sufficient power for the statistical test was 
required to detect an increase of the rate of patients deciding 
to use the HC syringe for future MTX treatment to at least 
70%. A one-group chi-square test with a 5% two-sided 
significance level would have 90% power to detect the 
difference between the null hypothesis rate of 55% and the 
alternative rate of 70% with a sample size of 110 patients. 
  To assess the local tolerability at the site of injection, 
frequency distributions of mild, moderate and severe signs 
and symptoms of swelling, itching, erythema, haematoma 
and pain were presented. Treatment-specific differences 
between ordinal data were evaluated using Wilcoxon signed-
rank tests on an explorative perspective. All other parameters 
were analysed descriptively using robust measures of 
location and dispersion such as medians and 1
st (Q1) and 3
rd 
quartiles (Q3). 
Table 1.  Preference and Usability Outcomes* 
 
Patient-Reported Outcomes 
Overall preference (primary endpoint) 
“Which of the pre-filled syringes would you prefer from now on?” 
Patient satisfaction 
“How would you assess, in summary, the small/large syringe at the end of the study?” 
Five categories were suggested: “very poor”, “poor”, “no preference”, “good” and “very good”. 
Syringe with or without pre-attached needle 
“How do you like the pre-attached needle (small syringe) in comparison to one that still has to be attached (large syringe)?” 
Five categories were suggested: “great disadvantage”, “disadvantage”, “no difference”, “advantage”, and “great advantage”. 
Usability of syringe volume 
“Do you feel comfortable with the fact that the injection liquid is five times less in the small syringe than in the large syringe?” 
Five possible answers were suggested: “fully disagree”, ”disagree”, ”indifferent”, “agree” and “fully agree”. 
Local tolerability 
Occurrence of erythema, swelling, itching, pain and haematoma assessed as “none”, “mild”, “moderate” or “severe”. 
Usability of the 10 mg/ml syringe at the 2
nd and 3
rd injection (MC formulation) and of the 50 mg/ml syringe at the 5
th and 6
th injection (HC 
formulation) 
Rated on a visual scale from 0 (not convenient = 0 mm) to 10 (very convenient = 100 mm). 
Physician-Reported Outcomes 
Usability of the 10 mg/ml syringe at the 1
st injection (MC formulation) and of the 50 mg/ml syringe at the 4
th injection (HC formulation) 
Rated on a visual scale from 0 (not convenient = 0 mm) to 10 (very convenient = 100 mm). 
Local tolerability 
Occurrence of erythema, swelling, itching, pain and haematoma assessed as “none”, “mild”, “moderate” or “severe”. 
Study Nurse/Physician-Reported Outcomes 
Syringe with or without pre-attached needle 
“How do you like the pre-attached needle (small syringe) in comparison to the one which still has to be attached (large syringe)?” 
Five categories were suggested: “great disadvantage”, “disadvantage”, “no difference”, “advantage”, and “great advantage”. 
Usability of syringe volume 
“Do you feel comfortable with the fact that the injection liquid is five times less in the small syringe than in the large syringe?” 
Five possible answers were suggested: “fully disagree”, ”disagree”, ”indifferent”, “agree” and “fully agree”. 
Overall assessment of the small prefilled syringe 
Five categories were suggested: “very poor”, “poor”, “no preference”, “good” and “very good”. 
Overall assessment of the large prefilled syringe 
Five categories were suggested: “very poor”, “poor”, “no preference”, “good” and “very good”. 
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Fig. (1). Comparison of the methotrexate prefilled syringe 
10 mg/ml and 50 mg/ml true to scale. MTX=methotrexate.  
Ethics 
  The study was performed in accordance with the Good 
Clinical Practice guidelines recommended by the 
International Conference on Harmonization (ICH) of 
Technical Requirements. Ethics committees relevant to the 
respective study sites approved the study protocol. Written 
informed consent was obtained from all patients. 
Funding 
  The study was supported by medac Gesellschaft für 
klinische Spezialpräparate mbH, Hamburg, Germany. 
RESULTS 
Patient Characteristics 
  Of the 132 patients enrolled, one was excluded from the 
safety-analysis set (due to missing study visits (1
st, 2
nd and 
4
th injection) and lack of any source data) and additional 3 
were excluded from the full-analysis set (due to injection of 
merely one type of syringe). Of the 128 patients included in 
the full-analysis set, 34 were men and 94 women. Median 
age was 56 years (range: 18 to 75 years), median weight 
78 kg (range: 49 to 116 kg) and median body height 165 cm 
(range: 150 to 188 cm). Median baseline Disease Activity 
Score of 28 joints (DAS28) was 4.3 (range 2 to 8) and 
median duration of RA in the patients was 3 years (range: 1 
to 39 years). Sixty-three (49.2%) patients had previously 
received MTX treatment at dosages ranging between 7.5 to 
25 mg/week and differed from those dosages given at study 
start. 85.1% of the patients received MTX dosages of 15 or 
20 mg/week (6 patients received more than 20mg oral MTX, 
1 patient received 25 mg, the other ones 22.5 mg). 
Efficacy 
Patient-Reported Outcomes 
  The primary efficacy variable was to quantify the 
decision of the patient for future MTX treatment (50 mg/ml 
syringe  vs 10 mg/ml syringe) following repeated SC 
injections of both formulations. At the end of the study, 
93.0% of all patients stated that they would prefer the HC 
formulation compared to 2.3% of the patients expressing a 
preference for the MC formulation (95% confidence interval: 
[87.1%; 96.7%]). The result was highly statistically 
significant (P<0.0001). 
  At the end of the study, overall assessment of the patients 
of the HC formulation was “good” and “very good” in 
90.6% of the patients compared to 1.6% with a “poor” and 
“very poor” overall assessment. The patients’ overall 
assessment of the MC formulation was “good” and “very 
good” in 34.4% of the patients compared to 17.2% with a 
“poor” and “very poor” overall assessment (Fig. 2). This 
advantage in favour of the HC formulation was statistically 
significant (P<0.0001). 
  89.1% of the patients assessed the usability of having a 
pre-attached needle with the small syringe (HC formulation) 
as an “advantage” and “great advantage” and 3.1% as a 
“disadvantage” and “great disadvantage”.  
  87.5% of the patients reported that the smaller volume in 
the HC formulation was more suitable (“agree” and “fully 
agree”) compared to the larger volume with the MC 
formulation. 1.6% of the patients disagreed in this regard.  
  Using a visual analogue scale, patient’s global 
assessment of syringe usability was 63.5 mm (Q1-Q3: 49-
92) after MC administrations which increased significantly 
to 95.0 mm (Q1-Q3: 85-99) after administration of the HC 
formulation (P < 0.0001). 
Physician-Reported Outcomes 
  Using a visual analogue scale, physician-reported global 
assessment of syringe usability was 82.0 mm (Q1-Q3: 59-
100) at the time of administration of the MC formulation. A 
significant increase in to 96.0 mm (Q1-Q3: 86-100) was 
observed at time of HC administration (P < 0.0001). 
Study Nurse/Physician-Reported Outcomes 
  All study nurses and physicians assessed the usability of 
having a pre-attached needle with the small syringe (HC 
formulation) as an “advantage” or “great advantage”. 
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  87.5% found that the smaller volume in the HC 
formulation was more suitable (“agree” and “fully agree”) 
compared to the larger volume with the MC formulation. 
12.5% saw no difference in this regard. 
  At the end of the study, study nurses’ and investigators’ 
overall assessment of the HC formulation was “good” 
(18.8%) and “very good” (81.2%). The overall assessment of 
the MC formulation was “good” in 31.3% of cases, “very 
good” in 12.5% and no preference in 50% (Fig. 3). 
Safety 
  Adverse events were coded according to the Medical 
Dictionary for Regulatory Affairs (MedDRA). Adverse 
events were reported in 25 (19.1%) of the 131 patients valid 
for safety analysis. The number of patients experiencing 
adverse events was 14 (10.7%) and 15 (11.5%) with MC and 
HC formulation, respectively (Table 2).  
  All adverse events expect the one documented within the 
system organ class “Injury, poising and procedural 
complications” were judged to be at least possibly drug-
related. The most frequent adverse events and drug-related 
adverse events were gastrointestinal disorders (6.1%), 
investigations (3.8%) and general disorders and 
administration site conditions irritations (3.1%). Most 
adverse events were of mild and moderate intensity. No 
relevant differences were observed between the two MTX 
formulations with the exception of five  cases of mild and 
moderate increases in liver enzymes documented within the 
 
Fig. (2). Patients’ overall assessment of methotrexate prefilled syringe 10 mg/ml and 50 mg/ml.  
 
Fig. (3). Study nurses’ and physicians’ overall assessment of methotrexate prefilled syringe 10 mg/ml and 50 mg/ml.  20   The Open Rheumatology Journal, 2010, Volume 4  Müller-Ladner et al. 
system organ class investigations occurring during HC 
treatment compared to no cases during MC treatment. 
  Three serious adverse events were reported: One 
occurred during HC-treatment phase two days after the 5
th 
injection (cheek bone fracture) and two others (back pain and 
left ear mastoiditis)  within 28 days after the final 
examination. All events were considered unrelated to study 
medication by the investigator. 
  Three subjects discontinued study participation due to 
adverse events. These included coughing, dizziness and 
nausea/sicca symptoms/pain. All events were non-serious 
and considered as possibly related to study medication. 
Table 2.  Adverse Events 
 
MedDRA System Organ Class/Preferred Terms 
MTX Medium 
Concentration 
n=131 
n (%) 
MTX High  
Concentration 
n=131 
n (%) 
Total 
n=131 
n (%) 
Number or patients with adverse events   14 (10.7)  15 (11.5)  25 (19.1) 
Gastrointestinal disorders   5 (3.8)  4 (3.1)  8 (6.1) 
Abdominal pain   0 (0.0)  2 (1.5)  2 (1.5) 
Abdominal pain upper  0 (0.0)  1 (0.8)  1 (0.8)  
Diarrhoea  2 (1.5)  0 (0.0)  2 (1.5) 
Mouth ulceration  1 (0.8)  0 (0.0)  1 (0.8)  
Nausea   3 (2.3)  1 (0.8)  4 (3.1) 
Investigations   0 (0.0)  5 (3.8)  5 (3.8) 
Alanine aminotransferase increased  0 (0.0)  5 (3.8)   5 (3.8)  
Aspartate aminotransferase increased   0 (0.0)  2 (1.5)  2 (1.5) 
Gamma-glutamyltransferase increased  0 (0.0)  1 (0.8)  1 (0.8) 
White blood cell count decreased   0 (0.0)  1 (0.8)  0 (0.0) 
General disorders and administration site conditions   3 (2.3)  2 (1.5)  4 (3.1) 
Fatigue   1 (0.8)  0 (0.0)  1 (0.8) 
Feeling abnormal  1 (0.8)  0 (0.0)  1 (0.8) 
Injection site irritation   1 (0.8)  1 (0.8)  1 (0.8) 
Mucosal dryness   0 (0.0)  1 (0.8)  1 (0.8) 
Pain   0 (0.0)  1 (0.8)  1 (0.8) 
Skin and subcutaneous tissue disorders   2 (1.5)  1 (0.8)  3 (2.3) 
Alopecia  2 (1.5)  0 (0.0)  2 (1.5) 
Erythema  0 (0.0)  1 (0.8)  1 (0.8) 
Musculoskeletal and connective tissue disorders  1 (0.8)  2 (1.5)  2 (1.5) 
Musculoskeletal pain  0 (0.0)   1 (0.8)   1 (0.8) 
Myalgia  0 (0.0)   1 (0.8)   1 (0.8) 
Pain in extremity   0 (0.0)   1 (0.8)   1 (0.8) 
Rheumatoid arthritis (worsening)   1 (0.8)  0 (0.0)   1 (0.8) 
Nervous system disorders  1 (0.8)  1 (0.8)  2 (1.5) 
Cervical root pain   0 (0.0)  1 (0.8)  1 (0.8) 
Dizziness   1 (0.8)  0 (0.0)  1 (0.8) 
Respiratory, thoracic and mediastinal disorders/ Cough  2 (1.5)  0 (0.0)  2 (1.5) 
Infections and infestations/Oral herpes  1 (0.8)  0 (0.0)  1 (0.8) 
Ear and labyrinth disorders/Vertigo  0 (0.0)  1 (0.8)  1 (0.8) 
Injury, poisoning and procedural complications/Facial bones fracture  1 (0.8)  0 (0.0)  1 (0.8) 
Metabolism and nutrition disorders/Anorexia   1 (0.8)  0 (0.0)  1 (0.8) 
Vascular disorders Extremity necrosis  1 (0.8)  0 (0.0)  1 (0.8) Comparison of Two MTX Prefilled Syringes for S.C. Injection in RA  The Open Rheumatology Journal, 2010, Volume 4   21 
  With regard to overall local tolerability including 
erythema, swelling, itching, pain and haematoma at the 
injection site, HC treatment was slightly better tolerated than 
MC treatment. Physicians’ assessment of the injection site 
showed an absence of erythema with HC treatment in 79.7% 
of patients compared to 71.1% with MC treatment, which 
was statistically significant (P = 0.0123) and tended to be 
confirmed by patients’ assessment. 
  For all laboratory categories (haematology and 
biochemistry), mean parameter changes were minor 
including those of liver function tests. Except for a mean 
decrease in CRP by 4 mg/l, mean changes were of no clinical 
relevance. 
DISCUSSION 
  The results of the study show that repeat dosing of the 
novel high-concentration (HC) MTX solution available in a 
prefilled syringe with a pre-attached needle yields a 
significantly better acceptance by patients and healthcare 
professionals than the medium-concentration (MC) solution 
with a syringe to which the needle still has to be attached. 
  The MTX formulations differ also considerably with 
regard to usability and overall preference in numerous 
patients with RA who self-administered the prefilled MTX 
syringes. At the end of the study 93% of the patients 
preferred HC over MC as further treatment. Physicians’ and 
patients’ global assessments of syringe usability showed also 
highly statistically significant differences (P  < 0.0001) in 
favour of the HC formulation. 
  Reasons for this preference also include a smaller volume 
of administered drug, which improves the comfort of 
injection and may represent a psychological benefit for the 
patient. In addition, the pre-attached needle (HC 
formulation) allows a safer handling in comparison to the 
MC syringe, for which the needle must first be attached to 
the syringe body. 
  A within patient-controlled design was considered the 
most appropriate approach to determine whether the switch 
to the newly available HC treatment has the ability to 
increase patient’s satisfaction of subcutaneous MTX 
treatment compared to the previously available MC 
treatment. Due to different sizes of syringes blinding of 
patients and nurses was not feasible within this trial. 
However, the study results may be biased due to the fact that 
the treatment sequence was not randomized. But, looking at 
the huge numerical advantage of HC, this bias can be 
considered to be negligible with respect to the overall study 
conclusion. 
  Differences regarding local tolerability were slightly in 
favour of HC treatment. Erythema occurred significantly less 
often with HC treatment compared to MC treatment. Overall 
patient assessment was confirmed by physician and study 
nurse assessments who expressed similar preferences and 
conclusions as the patients. In general, quantity and quality 
of adverse events did not differ between the two 
formulations to a relevant extent. 
  This study focused on safety and tolerability and not on 
efficacy. However, as the superior efficacy of SC 
administered MTX has been proven in a recent 6-month, 
multicenter, randomized, double-blind, controlled trial in 
comparison to oral MTX in 384 MTX-naïve patients with 
active RA [5], similar clinical results can be expected for the 
novel HC formulation. Parenteral MTX treatment is in 
accordance with current practice guidelines which 
recommend to consider a switch to the intramuscular or SC 
route in patients with poor compliance, inadequate 
effectiveness, or gastrointestinal side effects [8, 9]. Taking 
into account the evidence from other studies which have 
confirmed the improved usability and tolerability of SC 
administration of MTX also in comparison to intramuscular 
injection [2-4], the newly developed 50 mg/ml prefilled 
syringe appears to be a highly preferred treatment option for 
patients with RA in need of MTX. This is supported by the 
strong appreciation of the patients as well as their attending 
healthcare professionals for its usability and tolerability. 
CONCLUSIONS 
  A smaller volume of administered drug, the usability of 
being able to use a pre-attached needle with the small 
prefilled syringe and an improved local tolerability have 
contributed to the preference of the HC small syringe to 
apply subcutaneous MTX in active RA patients. This 
assessment was supported by similar assessments made by 
physicians and study nurses. With the exception of erythema 
which occurred significantly less often with HC treatment 
quality and quantity of adverse events did in general not 
differ between the two formulations. 
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KEY MESSAGES 
  Patients, physicians and nursing staff prefer a high-
concentration prefilled syringe over a medium-concentration 
syringe for SC administration of MTX. 
  Superior usability and overall satisfaction contributed to 
this preference. Local tolerability trended to be advantageous 
for HC and was partly significant for erythema. 22   The Open Rheumatology Journal, 2010, Volume 4  Müller-Ladner et al. 
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